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Abstract 
Purpose: To formulate extended-release tablets of diclofenac sodium based on ispaghula husk 
Methods: Tablets with varying proportions of diclofenac sodium and ispaghula husk were formulated by 
wet granulation technique at a fixed compression force of 10 kN. The formulated tablets were evaluated 
for physicochemical parameters as well as by Fourier transform infrared spectroscopy (FTIR), differential 
scanning calorimetry (DSC) and x-ray diffraction (XRD).  
Results: Content uniformity, weight variation, thickness and friability of the formulated tablets were 
within acceptable limits. The hardness of the tablet decreased from 5.4 to 4.2 kg/cm2 with increasing 
quantity of ispaghula husk in the formulation. In contrast, disintegration time increased from 12 to 70 
min with increasing amount of husk. Tablets formulated with 1:0.25 and 1:0.5 drug/husk ratio failed to 
extend drug release whereas tablets prepared with 1:0.75 and 1:1 ratio extended release up to 5 and 6 
h, respectively.  FTIR, DSC and XRD analysis of tablets revealed the absence of diclofenac–ispaghula 
interaction and crystalline nature of diclofenac sodium. Drug release data fitted well with Korsmeyar-
Peppas and the n value of 0.98 indicate non-Fickian diffusion.  The tablets were stable on storage and 
retained its physicochemical properties within acceptable limits.  
 Conclusion: The results indicate the possibility of formulating extended-release tablets based on 
ispaghula husk. The tablets were stable during storage and free from drug-excipient interactions. 
However further studies are required to ascertain the safety of the husk and to optimize the release 
properties of the tablets. 
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Ispaghula husk is obtained from dried ripe seeds 
of Plantago ovata Forkal which belongs to the 
family, Plantaginaceae. Psyllium consists of the 
seeds of Plantago psyllium and Plantago 
arenaria.  Ispaghula and Psyllium are invariably 
named as psyllium [1] in the literature. The US 
National Formulary [2] includes all three species 
under the name “Plantago seed." The BP/EP 
classifies the husk of Plantago ovata as 
ispaghula and other two as psyllium [3]. All these 
seeds contain mucilage, and it hydrolysis [1, 4] 
yields D-xylose, L-arabinose, D-galactose and D-
galacturonic acid.  
 
Ispaghula (also called as isapgol) husk and 
psyllium regulate bowel function and are 
available as over the counter drugs to treat 
constipation. Both recently received attention in 
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tablet technology as disintegrating agent [5] 
release retardant [6] and floatation agent [7]. The 
intended application was achieved with the 
ispaghula/Psyllium alone [6, 8] or in combination 
with other polymers [9]. The unique nature of 
ispaghula husk is higher swelling factor (40 - 90), 
as it swells 4 - 5 times more than psyllium. In 
general, more swelling allows the drug to diffuse 
along a lengthier path length and thus produces 
extended release from the swollen matrix. 
 
Extended release of drug from swellable matrix 
tablets [10] mainly depends on the nature of the 
polymer, drug solubility, drug-polymer ratio, 
particle size, moisture content of the granule and 
the force applied to produce tablets. No 
information is available in the literature about the 
compression force and the moisture content of 
granules employed in ispaghula-based extended 
release tablets. Hence, an attempt is made to 
formulate ispaghula husk based extended 






Diclofenac sodium was received as a gift from 
Cassel Research Lab., Chennai, India.  
Ispaghula (Plantago ovata) was purchased from 
Sidhpur Sat-Isapgol factory, Sidhpur, Gujarat, 
India. Magnesium stearate IP was procured from 
Sinai Pharma Pvt Ltd, India.  Lactose IP was 
purchased from Lactose India Ltd.  All other 
chemicals used were of analytical grade. 
 
Preparation of ispaghula husk-based 
extended release tablets  
 
The husk was powdered and passed through the 
sieve #30. Other ingredients were passed 
through the sieve # 40. The tablet ingredients 
listed in Table 1 mixed in a rapid mixer-
granulator (Rotamix HSMG-10, Kevin Engineers, 
India) for 5 min.  A sufficient quantity of starch 
paste (10 %) was added in divided portions to 
the mixed powder and granulated in a rapid 
mixer granulator. The wet granules were passed 
through a sieve of 1000 µm size and dried at 40 
C for 30 min in a tray drier (Bombay 
Engineering Works, India).  The moisture content 
was determined by Karl Fischer method (Karl - 
Fischer titrator, Precision V/M MD, India) and 
drying continued until the moisture content fell to 
between 5.0 and 5.5 % w/w.  The dried granules 
were passed through the sieve of 1410 µm size, 
lubricated with   magnesium stearate (1 % w/w) 
and talc (1 %w/w) and then compressed with a 
force of 10 kN using 11 mm flat punches in a 
tablet compression machine (Clit, CJD3 20 
stations) to obtain tablets of approximately 400 




Twenty tablets were weighed and powdered.  
The quantity equivalent to 50 mg of diclofenac 
sodium was weighed accurately and taken in a 
200 ml volumetric flask. Phosphate buffer (60 ml, 
pH 7.4) was added to the flask and sonicated 
(Sonicator- Branson, SmithKline) for 5 min. The 
volume was made up to 200 ml with phosphate 
buffer. After filtration (Whatman filter paper, no. 
1) and appropriate dilution, diclofenac sodium 
content was determined at 276 nm [11] using a 





 The formulated tablets were tested [12] for 
weight variation, thickness, friability, hardness 
and disintegration. The weight of 20 tablets from 
each batch was taken using an electronic 
balance (Mettler Toledo, PL 303) and the mean 
weight calculated. The tablets were weighed 
individually to determine the variation from 
average weight.  The individual thickness of 10 
tablets from each batch was measured using a 
Vernier caliper. Preweighed tablets (n = 20) 
tablets were placed and rotated in friability test 
apparatus (Hicon, India). The tablets were 
weighed once again after 100 revolutions to find 
out the weight loss. The hardness of 6 tablets 
was measured using a hardness tester (Dr 
Schleuniger Pharmatron, India) and the mean 
calculated. Disintegration test was carried out on 
6 tablets using a tablet disintegration apparatus 
(Sakti Scientific, India) and water as medium. 
Each tablet was dropped in the moving (30 
cycles per min) glass tube (n = 6) immersed in 
1000 ml of medium maintained at 37  2C. The 
time required to disintegrate each tablet was 
noted visually. 
 
Fourier transform infrared spectroscopy 
(FTIR) 
 
The infrared spectra of the powdered tablet and 
diclofenac sodium were recorded on a Nicolet 20 
DXB FTIR spectrophotometer using KBr pellet 
technique. The tablets were powdered in a 
mortar and pestle, mixed with KBr and 
compressed to produce pellets using a hydraulic 
press. Diclofenac sodium and husk were used as 
such to make KBr pellets. 
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Differential scanning calorimetry 
 
Differential scanning calorimetry (DSC) analysis 
of diclofenac sodium and powdered tablets were 
done using Perkin-Elmer DSC7 model.  The 
instrument was calibrated with indium.  All the 
samples ( 5 mg) were heated in sealed 
aluminum pans with perforated lid using dry 
nitrogen as the effluent gas.  The analysis was 
performed over the heating range of 50 – 300 °C 
at a rate of 20 °C min-1. 
 
 X-ray diffraction 
 
Diclofenac sodium and powdered tablets were 
analyzed using an x-ray diffractometer (XD-D1, 
Shimadzu, Japan) in the 2 range 5 - 80º. 
Operating conditions include CuK radiation, 30 
kV, 20 mA and a slit of 1-1-0.3 mm. 
 
In vitro release studies  
 
The in vitro release study of diclofenac sodium 
from the formulated tablets was carried out in 
900 ml of phosphate buffer (pH 7.4) using a USP 
dissolution apparatus 1 (model TDT 067, 
Electrolab, India) at 37  2C and 100 rpm. 
Samples were taken at regular intervals and 
diclofenac content measured spectrophoto-
metrically at 276 nm [11].  
 
Drug release kinetics 
 
The data obtained from in vitro release studies 
were fitted to various kinetic equations [11] to 
determine the mechanism of drug release from 
the tablets.  The kinetic models used were zero 
order equation, first order equation and Higuchi 
release, i.e., Qt vs t, log (Q0-Qt) vs t and Qt vs 
square root of t, respectively; where Qt is the 
amount of drug released at time t and Q0 is the 
initial amount of drug present in the tablets. To 
further ascertain the mechanism of drug release, 
the first 60 % of drug release was fitted to 
Korsmeyer-Peppas model (Eq 1). 
 
 Mt/M = ktn …………………………….. (1) 
 where Mt/M is the fraction of drug released at 
time, t; k is the rate constant and n is the release 
exponent.  The n value is used to characterize 
different release mechanisms. 
 
Stability studies  
 
The tablets (batch 4) were kept for a short term 
accelerated stability study in a high-density 
polyethylene bags with a sealed cover at 40 ± 
2C/75 ± 5 %RH as per International Convention 
on Harmonization (ICH) guidelines.  Samples 
were withdrawn after 1, 2 and 3 months of 
storage and evaluated [12] for appearance, 




Drug loading, entrapment and encapsulation 
efficiency data were analyzed using independent 
sample t-test while drug release data were 
analyzed using ANOVA. PASW 18 statistics 
software (IBM, USA) was used for statistical 





Physicochemical characteristics of ispaghula 
tablets 
 
The physical and chemical parameters of the 
formulated tablets are presented in Table 1.  
Physicochemical parameters such as uniformity 
in drug content, thickness, friability and weight 
variation of the tablets were within the acceptable 
limits stipulated in British Pharmacopoeia. Drug 
content, thickness and weight of all formulated 
tablets were within 5 % variation (p > 0.05) and 
the % of loss during friability test was less than 1  
 
Table 1: Composition and characteristics of formulated tablets                
 
 Batch 1 Batch 2 Batch 3 Batch 4 
Composition per tablet  
Drug: Isapgol 1:0.25 1:0.5 1: 0.75 1:1 
Diclofenac sodium (mg) 100  100  100  100  
Isapgol husk (mg) 25  50  75  100  
Starch (mg) 100  100  100  100 
Lactose (mg) 175 150  125  100  
Physicochemical properties 
Disintegration time (min) 12.0±1.7  16.0±2.2  30.0±3.2  70.0± 3.2  
Hardness ( kg/cm2) 5.40±0.18  5.20±0.26  4.80±0.34  4.20±0.23  
Thickness (mm) 3.14±0.04  3.18±0.08  3.20±0.05  3.22±0.08  
Friability (%) 0.92  0.89  0.91  0.89  
Average weight (mg) 401.0±1.7  398.0±2.1  405±1.1  409.0±1.63  
Drug content (% w/w) 99.6 ± 0.7  100.4 ± 1.1  99.2±1.8  102.1±1.5  
Results are expressed as mean ± SD. 
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% w/w (p > 0.05). Each batch of tablets was 
found consistent with respect to measured 
hardness (5.4 to 4.2 kg/cm2, p > 0.05). The 
tablet hardness was decreased as husk 
proportion increased in the formulation. 
Batch 4 tablets showed longer disintegration 
time (70 min, p < 0.05) than tablets of other 
batches in spite of their lower hardness.  
 
Fourier transform infrared spectroscopy 
 
The FTIR spectrum of ispaghula (Figure 1A) 
showed identical peaks similar to those already 
reported in literature [13, 14]. The FTIR spectrum 
of diclofenac sodium (Figure 1B) showed 
characteristic peaks at 1167 and 682 cm-1 for 
aromatic –C-Cl. The stretches between 800 and 
600 cm-1 also support the presence of –C-Cl 
group. The strong peaks in the region of 1600 – 
1700 - 1800 cm-1 indicate the presence of -C=O. 
Furthermore, the presence of peaks in the region 
of 1200, 1283 and 1044 cm-1 confirms –C-O- 
group. The peaks at 1603, 1507 and 869-716 
cm-1 indicate the presence of the aromatic ring. 
Similar peaks also appeared in the spectrum of 
drug-containing tablets (Figure 1C). We 
previously reported similar findings for diclofenac 




The thermogram of ispaghula husk (Figure 2) did 
not show any peak and indicated its amorphous 
nature. The thermogram of diclofenac sodium 
showed a crystalline peak at 296 ºC, same as for 
the physical mixture of diclofenac sodium: husk 
as well as the tablet formulation. The extent of 
the peak increased as the degree of crystallinity 
of the drug in the formulation increased. 
 
X-ray diffraction (XRD) 
 
The XRD of ispaghula husk did not produce any 
sharp peak (Figure 3) and confirmed its 
amorphous nature. The XRD of diclofenac 
sodium showed sharp peaks in the region 10 – 
20 o, indicating the crystalline nature of the drug. 
These peaks also appeared in the diffractogram 
of the tablet formulations.  
 
In vitro drug release 
 
In vitro release profiles of diclofenac sodium from 
the tablets are shown in Figure 4. Batches 1 and 
2 did not show extended release of the drug 
whereas batches 3 and 4 extended drug release 
up to 5 and 6 h, respectively. There was no 
significant difference (p > 0.05) between the 
release profiles of diclofenac sodium from batch 
1 and 2 tablets but release was significant (p < 
0.05) between batches 3 and 4. 
 
Drug release kinetics and release mechanism 
 
The first 90 % release data of batches 3 and 4 
tablets were fitted to various kinetic models. The 
best fit (highest correlation coefficient) was first 
order model (r2 = 0.9720 and 0.9852 for batches 
3 and 4, respectively.) followed by Higuchi 
(diffusion controlled, r2 = 0.9662 and 0.9678 for 
batches 3 and 4, respectively); zero order (r2 < 
0.9517); and Hixson-Crowell or modified cube 
root (dissolution controlled, showed poor 
correlation (r2 < 0.7328).  When the first 60 % 
drug release data were fitted to Korsmeyer-
Peppas model for batch 4 tablets, it yielded a 
value of r2 = 0.9829 and n value of 0.98.
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Figure  2:  DSC thermograms of diclofenac sodium 
(A), physical mixture of diclofenac sodium and husk 
(1:1) (B), batch 4 tablet (C) and isapgol husk (D). 
 
                                                                     
Figure 3:  X-ray diffraction of diclofenac sodium (A), 
tablet formulation (batch 4, B) and isapgol husk (C) 
 
Storage stability  
 
The tablets largely retained their 
physicochemical properties under accelerated 
storage conditions, showing less than 5 % 
variation in their original values as shown in 
Table 1. Almost same release profile (p > 0.05) 




Tablets formulated with 1:1 ratio of 
ispaghula/diclofenac sodium showed lower 
hardness than other batches. Increase in husk 
content resulted in weaker tablets.  This could be 
due to the soft nature and poor compressibility of 
ispaghula husk. A higher proportion of ispaghula 
in the formulated tablets also prolonged 
disintegration time.  
 
 
Figure 4:  In vitro release of diclofenac sodium from 
batch 1 (), 2 (■), 3 (▲) and 4 (●) tablets 
     
FTIR is capable of indicating a potential chemical 
interaction in a formulation. The spectra indicate 
that there was no chemical interaction. This was 
confirmed by both DSC and XRD results. DSC 
and XRD also confirmed that the crystalline 
nature of drug was retained in the formulated 
tablets. 
 
More than 90 % of the drug in batches 1 and 2 
tablets was released within 1 h due to the rapid 
disintegration of these tablets  Batch 3 and 4 
tablets disintegrated in 30 and 70 min, 
respectively. Batch 3 formulation extended 
release in a bi-phasic manner. An initial burst 
release was observed for batches 3 and 4 
probably due to the free drug present on the 
surface of the tablets as well as faster swelling of 
husk matrix which is beneficial as it could serve 
as prompt dose for immediate pharmacological 
activity.  
 
Drug release from batches 3 and 4 tablets 
followed first order kinetics more closely than the 
other release models. The release exponent, n, 
value of 0.98 obtained from Korsmeyer-Peppas 
analysis indicates non-Fickian diffusion [15].  
Thus, drug release from the tablets is swelling-
controlled rather than diffusion-controlled. A 
similar release mechanism has previously been 
observed for arabinoxylans-based diclofenac 
sodium sustained release tablets [6]. The high n 
value of 0.98 (close to 1) also indicates that the 
initial 60 % release of loaded drug followed zero 
order kinetics [15]. It is also evidenced by the 
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% release. Later the release was slowed down 




The present study reveals the possibility of 
formulating extended release tablets using 
ispaghula husk as a sole release retarding 
polymer without interaction with diclofenac 
sodium. However, further studies are required to 
optimize both the physical and release properties 
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